

## REMARKS

Claims 1, 4-14, 17-19, and 21-25 remain in this application. Claims 1 and 11 are amended.

Support for the amendments can be found, for example, in claim 1 as filed.


The amendments are presenting rejected claims in better form for consideration for appeal (MPEP §1207). Claims 1 and 11 as amended do not recite treatment of disease, but only generating an immune response in recipients of the vaccines. Therefore, the enablement inquiry should be more narrowly focused on whether the specification enables eliciting an immune response to the *P. acnes* lipase, not on whether the specification enables such broad applications as reducing sizes of abscesses caused by *P. acnes*, total or partial prevention of Acne vulgaris, curing pre-existing conditions, etc.. Claims 1-10 and 12-14, 17, 18 21-23 depend from claims 1 or 11 and therefore incorporate the amended limitations.

## **CONCLUSION**

Claims 1, 4-14, 17-19, and 21-25 remain in this application. Applicants respectfully request entry of the amendments.

Date: 6/23/2004

Respectfully submitted,



Dennis Fernandez  
Attorney for Applicants  
Reg. No. 34,160  
(650) 325-4999